%0 Unpublished work %T Nebulized fusion inhibitory peptide protects cynomolgus macaques from measles virus infection %+ Centre International de Recherche en Infectiologie (CIRI) %+ DTF-Aerodrug %+ Infectiologie et Santé Publique (UMR ISP) %+ Université de Tours (UT) %+ Columbia University College of Physicians and Surgeons %+ Capital University of Medical Sciences [Beijing] (CUMS) %+ Centre d’Etude des Pathologies Respiratoires (CEPR), UMR 1100 (CEPR) %+ University of Washington Medical Center %+ Cornell University [New York] %+ Università degli studi della Campania "Luigi Vanvitelli" = University of the Study of Campania Luigi Vanvitelli %A Reynard, Olivier %A Gonzalez, Claudia %A Dumont, Claire %A Iampietro, Mathieu %A Ferren, Marion %A Guellec, Sandrine Le %A Lajoie, Laurie %A Mathieu, Cyrille %A Carpentier, Gabrielle %A Roseau, Georges %A Bovier, Francesca %A Zhu, Yun %A Pennec, Deborah Le %A Montharu, Jerome %A Addetia, Amin %A Greninger, Alexander %A Alabi, Christopher %A Moscona, Anne %A Vecellio, Laurent %A Porotto, Matteo %A Horvat, Branka %8 2022-10-20 %D 2022 %R 10.21203/rs.3.rs-1700877/v1 %M 35677066 %Z Life Sciences [q-bio]/Microbiology and Parasitology/Virology %Z Life Sciences [q-bio]/Human health and pathology/Emerging diseasesPreprints, Working Papers, ... %X Abstract Measles is the most contagious airborne viral infection and the leading cause of child death among vaccine-preventable diseases. We show here that aerosolized lipopeptide fusion inhibitors, derived from heptad-repeat regions of the measles virus (MeV) fusion protein, block respiratory MeV infection in a non-human primate model, the cynomolgus macaque. We used a custom-designed mesh nebulizer to ensure efficient aerosol delivery of peptides to the respiratory tract and demonstrated the absence of adverse effects and lung pathology in macaques. The nebulized peptide efficiently prevented MeV infection, resulting in the complete absence of MeV RNA, MeV-infected cells, and MeV-specific humoral responses in treated animals. This strategy provides an additional shield which complements vaccination to fight against respiratory infection, presenting a proof-of-concept for the aerosol delivery of fusion inhibitory peptides to protect against measles and other airborne viruses, including SARS-CoV-2, in case of high-risk exposure, that can be readily translated to human trials. %G English %2 https://cnrs.hal.science/hal-03777084/document %2 https://cnrs.hal.science/hal-03777084/file/v1_covered.pdf %L hal-03777084 %U https://cnrs.hal.science/hal-03777084 %~ ENS-LYON %~ UNIV-TOURS %~ CNRS %~ UNIV-LYON1 %~ CIRI %~ UDL %~ UNIV-LYON %~ INRAE %~ INFECTIOLOGIE-SANTE-PUBLIQUE %~ MICA-UNITES %~ INRAEVALDELOIRE %~ CEPR %~ TEST3-HALCNRS %~ RESEAU-EAU